Viral vectors and viral vaccines based on recombinant porcine adenoviruses
CA 2362454 C · Owner: Eloit, Marc · Inventors: Klonjkowski, Bernard Georges; Eloit, Marc
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to an in vivo replicative and recombined porcine adenovirus characterized in that it comprises a heterologous nucleotide , sequence inserted into the porcine adenovirus in conditions enabling the latter to , be replicated in vivo and to express the inserted heterologous nucleotide sequence, and in that the adenovirus genome comes from a 3 or 5 serotype (PAV-3 or PAV-5) adenovirus. Insertion occurs in a non-essential zone of the E3 , region, preferably with deletion of said zone. The invention also relates to a recombined porcine vaccine comprising one such porcine adenovirus. The invention further relates to a serotype 3 or 5 porcine adenovirus vector that is …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 8, 2000 and granted December 20, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 8, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 8, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.